drugset / Trial / NCT06104488

A Study of Avutometinib for People With Solid Tumor Cancers

NCT06104488

Phase 1 Active not recruiting 3 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.

Timeline

Start
2023-10-20
Primary completion
2029-10-20
Completion
2029-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Avutometinib Small molecule Oral